Issue 8, 2016

The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout

Abstract

A novel series of low molecular weight and synthetically facile acidic sulfonamides that are potent and selective URAT1 inhibitors is described. Compounds 46 and 47 were identified as promising leads from in vitro pharmacology and ADME profiling and advanced to broader in vitro and in vivo PK and toxicology studies.

Graphical abstract: The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout

Supplementary files

Article information

Article type
Research Article
Submitted
04 Apr 2016
Accepted
03 Jun 2016
First published
08 Jun 2016

Med. Chem. Commun., 2016,7, 1572-1579

The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout

A. Pike, R. I. Storer, R. M. Owen, E. Armstrong, C. L. Benn, M. Bictash, K. F. K. Cheung, K. Costelloe, E. Dardennes, E. Impey, P. H. Milliken, E. Mortimer-Cassen and H. J. Pearce, Med. Chem. Commun., 2016, 7, 1572 DOI: 10.1039/C6MD00191B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements